Pfizer Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Investigational Gene Therapy PF-06939926
NEW YORK--(BUSINESS WIRE)--October 01, 2020 -- Pfizer Inc. (NYSE: PFE) today announced that its investigational gene therapy candidate (PF-06939926) being developed to treat Duchenne muscular dystrophy (DMD) received Fast Track designation from the...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Clinical Trials | Gene Therapy | Genetics | Muscular Dystrophy | Pfizer | Pharmaceuticals | Reflex Sympathetic Dystrophy